Rezolute (Nasdaq:RZLT) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

RZLT Aperçu des actions

RZLT analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	2/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Se négocie à 88.7% en dessous de notre estimation de sa juste valeur

Les revenus devraient augmenter 61.73% par an

Analyse des risques

Réalise moins d'un million de dollars de revenus ( $0 )

Les actionnaires ont été considérablement dilués au cours de l'année écoulée

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Volatilité du cours de l'action au cours des 3 derniers mois

Rezolute, Inc. Concurrents

Biomea Fusion

NasdaqGS:BMEA

US$265.4m

Zura Bio

NasdaqCM:ZURA

US$261.0m

Design Therapeutics

NasdaqGS:DSGN

US$268.9m

Amarin

NasdaqGM:AMRN

US$257.2m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Rezolute
Historique des cours de bourse
Prix actuel de l'action	US$4.76
Plus haut sur 52 semaines	US$6.10
Plus bas sur 52 semaines	US$0.72
Bêta	1.21
1Variation sur 1 mois	10.70%
Variation sur 3 mois	2.37%
Variation sur 1 an	226.03%
3Variation sur 3 ans	-48.48%
Variation sur 5 ans	-26.77%
Évolution depuis l'introduction en bourse	-99.28%

Nouvelles et mises à jour récentes

Recent updates

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

May 22

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Feb 13

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 21

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Jan 12

Rendement pour les actionnaires

	RZLT	US Biotechs	US Marché
7D	1.3%	0.1%	0.5%
1Y	226.0%	14.0%	22.7%

Rendement vs Industrie: RZLT a dépassé le secteur US Biotechs qui a rapporté 15.7 % au cours de l'année écoulée.

Rendement vs marché: RZLT a dépassé le marché US qui a rapporté 25.6 % au cours de l'année écoulée.

Volatilité des prix

Is RZLT's price volatile compared to industry and market?
RZLT volatility
RZLT Average Weekly Movement	12.7%
Biotechs Industry Average Movement	10.4%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: RZLT n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de RZLT ( 14% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2010	41	Nevan Elam	www.rezolutebio.com

Rezolute, Inc. est une société biopharmaceutique en phase clinique qui développe des thérapies pour les maladies métaboliques associées à un déséquilibre chronique du glucose aux États-Unis. Le principal produit candidat de la société est le RZ358, un anticorps monoclonal humain qui fait l'objet d'un essai clinique de phase 2b pour le traitement de l'hyperinsulinisme congénital, une maladie génétique pédiatrique très rare. Elle développe également le RZ402, un inhibiteur oral de la kallikréine plasmatique, qui est en cours d'essai clinique pour le traitement chronique de l'œdème maculaire diabétique.

Rezolute, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Rezolute se comparent-ils à sa capitalisation boursière ?
RZLT statistiques fondamentales
Capitalisation boursière	US$263.50m
Bénéfices(TTM)	-US$58.21m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-4.5x

Ratio P/E

Le site RZLT est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
RZLT compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$0
Marge brute	US$0
Autres dépenses	US$58.21m
Les revenus	-US$58.21m

Derniers bénéfices déclarés

Mar 31, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.05
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de RZLT?

Voir les performances historiques et les comparaisons

RZLT Aperçu des actions

Récompenses

Analyse des risques

Rezolute, Inc. Concurrents

NasdaqGS:BMEA

US$265.4m

NasdaqCM:ZURA

US$261.0m

NasdaqGS:DSGN

US$268.9m

NasdaqGM:AMRN

US$257.2m

Historique des prix et performances

Nouvelles et mises à jour récentes

New major risk - Shareholder dilution

Rezolute, Inc. Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Price target increased by 9.4% to US$10.57

Recent updates

New major risk - Shareholder dilution

Rezolute, Inc. Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Price target increased by 9.4% to US$10.57

Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Chief Financial Officer recently bought US$67k worth of stock

Price target increased by 9.0% to US$8.50

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Now 29% overvalued after recent price rise

Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema

Rezolute Receives a Written Notice from the Listing Qualifications Department of Nasdaq Stock Market

New minor risk - Shareholder dilution

New minor risk - Share price stability

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

New major risk - Revenue and earnings growth

Price target decreased by 30% to US$7.80

Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358

Rezolute, Inc. to Report Q3, 2023 Results on May 11, 2023

Price target decreased by 7.9% to US$11.60

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema

High number of new and inexperienced directors

Price target decreased to US$12.60

Rezolute GAAP EPS of -$0.37

Rezolute, Inc. Promotes Brian Roberts to Chief Medical Officer

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased to US$19.20

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $117.587085 million.

Rezolute, Inc. Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

Rezolute, Inc., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Rezolute, Inc Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Rezolute, Inc. Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies At ESPE 2021

Rezolute, Inc. Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

Rezolute, Inc. Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

Price target decreased to US$26.50

High number of new and inexperienced directors

Price target decreased to US$27.00

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

Rezolute, Inc. Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

Rezolute shares rise on positive topline results from RZ402 eye disease trial

Rezolute, Inc. Announces Board Appointments

New 90-day low: US$11.98

Rezolute, Inc. Announces Phase 2B Study of RZ358 Continues to Enroll Congenital Hyperinsulinism (HI) Patients Worldwide

Rezolute Announces Initiation of Phase 1 Study of RZ402 for the Treatment of Diabetic Macular Edema

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

New 90-day low: US$12.94

Rezolute, Inc. Announces Resignation of Jung-Hee Lim as a Member of the Board of Directors, Audit Committee and Compensation Committee

Price target raised to US$31.50